Sequent Scientific is currently trading at Rs. 241.05, up by 5.40 points or 2.29% from its previous closing of Rs. 235.65 on the BSE.
The scrip opened at Rs. 243.00 and has touched a high and low of Rs. 247.00 and Rs. 237.55 respectively. So far 1,403 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 274.00 on 22-Apr-2014 and a 52 week low of Rs. 81.30 on 31-Jul-2013.
Last one week high and low of the scrip stood at Rs. 249.90 and Rs. 220.00 respectively. The current market cap of the company is Rs. 658.00 crore.
The promoters holding in the company stood at 65.35% while Institutions and Non-Institutions held 0.15% and 34.50% respectively.
Sequent Scientific has entered into a definitive agreement to acquire the manufacturing assets and business of Arvee Synthesis, Mysore (Arvee). Arvee would serve as a site for key intermediates for the company’s Human API business. The site has all necessary approvals and infrastructure with space for future expansion of SeQuent’s rapidly expanding business.
In another development, Sequent also acquired a land admeasuring 14 acres 24 Guntas, adjacent to its existing FDA approved facility in Mangalore. The facility at Mysore and land at Mangalore would be used for meeting the growing demand of Sequent’s key products in the USFDA and WHO regulated markets.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |